Managing Director & Partner
Related Expertise: Biopharma
Therapeutic biologics provide significant benefits to human health and address many unmet medical needs. Although several developed countries have established clear leads in biologics, China has the potential to build a world-class innovative biologics sector—if policies that support this ambition are formulated well and implemented in a timely manner.
As China aims to develop the biologics industry, three questions need to be answered: Are there lessons to be learned from the development of China’s small-molecule pharmaceutical and early-generation biologics sectors? How quickly can China catch up with leading countries in terms of breakthrough innovation? Can China’s largely unmet medical needs be translated into a meaningful market that can attract talent and economic activity and serve Chinese patients’ needs?
Building a World-Class, Innovative Therapeutic Biologics Industry in China commissioned by the R&D-based Pharmaceutical Association Committee in coordination with the Biotechnology Industry Organization, The Boston Consulting Group helps outline the moves China should take to aggressively position itself as a global leader in the innovative therapeutic-biologics industry.